Diaceutics (LON:DXRX) Issues Quarterly Earnings Results

Diaceutics (LON:DXRX) released its earnings results on Tuesday. The company reported GBX (3.27) earnings per share for the quarter, Digital Look Earnings reports. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%.

Diaceutics Stock Performance

Shares of DXRX traded up GBX 17.50 during mid-day trading on Tuesday, reaching GBX 187.50. The company had a trading volume of 845,169 shares, compared to its average volume of 199,838. The stock has a market capitalization of £159.11 million, a P/E ratio of 1,704.55 and a beta of 0.88. Diaceutics has a 52-week low of GBX 125 and a 52-week high of GBX 187.50. The stock has a 50 day moving average of GBX 145.09 and a two-hundred day moving average of GBX 150.64. The company has a quick ratio of 9.92, a current ratio of 3.43 and a debt-to-equity ratio of 2.85.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group reaffirmed a “buy” rating and issued a GBX 215 price objective on shares of Diaceutics in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Diaceutics currently has a consensus rating of “Buy” and a consensus price target of GBX 215.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.